BioMedNewsBreaks — IBN, BioMedWire Continue Collaboration to Amplify Reach of Dynamic Global Events’ 2025 Lineup

IBN, a leading communications organization with an extensive portfolio of over 60 brands, today announced its fifth consecutive year partnering with Dynamic Global Events (“DGE”) as an official media sponsor for 2025. BioMedWire (“BMW”), IBN’s digital platform dedicated to emerging life sciences opportunities, will also serve as a media partner, expanding DGE’s event reach and visibility throughout the year. DGE serves the pharmaceutical and life sciences sectors with educational B2B events that drive industry networking, partnership opportunities and business development.

“We are thrilled to extend our collaboration with IBN and BioMedWire for another year,” said DGE’s Head of Marketing, Elizabeth Sleiman, MBA. “IBN and BMW’s expertise in corporate communications, coupled with their vast syndication network and innovative multi-brand strategy, enhances the visibility and success of our event series.”

To view the full press release, visit https://ibn.fm/McLlW

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

7 hours ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial 

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial…

3 days ago

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica

Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A.…

3 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.…

3 days ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific…

4 days ago

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its…

4 days ago